Literature DB >> 8389989

An endogenous factor which interacts with synaptosomal membrane Na+, K(+)-ATPase activation by K+.

G Rodríguez de Lores Arnaiz1.   

Abstract

In previous papers, the isolation of brain soluble fractions able to modify neuronal Na+, K(+)-ATPase activity has been described. One of those fractions-peak I-stimulates membrane Na+, K(+)-ATPase while another-peak II-inhibits this enzyme activity, and has other ouabain-like properties. In the present study, synaptosomal membrane Na+, K(+)-ATPase was analyzed under several experimental conditions, using ATP or p-nitrophenylphosphate (p-NPP) as substrate, in the absence and presence of cerebral cortex peak II. Peak II inhibited K(+)-p-NPPase activity in a concentration dependent manner. Double reciprocal plots indicated that peak II uncompetitively inhibits K(+)-p-NPPase activity regarding substrate, Mg2+ and K+ concentration. Peak II failed to block the known K(+)-p-NPPase stimulation caused by ATP plus Na+. At various K+ concentrations, percentage K(+)-p-NPPase inhibition by peak II was similar regardless of the ATP plus Na+ presence, indicating lack of correlation with enzyme phosphorylation. Na+, K(+)-ATPase activity was decreased by peak II depending on K+ concentration. It is postulated that the inhibitory factor(s) present in peak II interfere(s) with enzyme activation by K+.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389989     DOI: 10.1007/bf00966778

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

1.  The Na,K-ATPase of nervous tissue.

Authors:  W L Stahl
Journal:  Neurochem Int       Date:  1986       Impact factor: 3.921

2.  Mass spectral characterization of an endogenous digitalislike factor from human plasma.

Authors:  W R Mathews; D W DuCharme; J M Hamlyn; D W Harris; F Mandel; M A Clark; J H Ludens
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

3.  Effect of Na+, K(+)-ATPase modifiers on high-affinity ouabain binding determined by quantitative autoradiography.

Authors:  M Antonelli; T Casillas; G Rodríguez de Lores Arnaiz
Journal:  J Neurosci Res       Date:  1991-03       Impact factor: 4.164

4.  Identification and characterization of a ouabain-like compound from human plasma.

Authors:  J M Hamlyn; M P Blaustein; S Bova; D W DuCharme; D W Harris; F Mandel; W R Mathews; J H Ludens
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

Review 5.  Isozymes of the Na+/K+-ATPase.

Authors:  K J Sweadner
Journal:  Biochim Biophys Acta       Date:  1989-05-09

6.  Regulation of (Na+, K+) adenosinetriphosphatase of nerve ending membranes: action of norepinephrine and a soluble factor.

Authors:  G Rodriguez De Lores Arnaiz; M Mistrorigo De Pacheco
Journal:  Neurochem Res       Date:  1978-12       Impact factor: 3.996

7.  Kinetics of oligomycin inhibition of sodium- and potassium-activated adenosine triphosphatase from beef brain.

Authors:  C E Inturrisi; E Titus
Journal:  Mol Pharmacol       Date:  1968-11       Impact factor: 4.436

8.  Studies on the partial reactions catalyzed by the (Na+ + K+)-activated ATPase. I. Effects of simple anions and nucleoside triphosphates on the alkali-cation specificity of the p-nitrophenylphosphatase.

Authors:  D Koyal; S N Rao; A Askari
Journal:  Biochim Biophys Acta       Date:  1971-01-05

9.  The effect of several neurotransmitter substances on nerve ending membrane ATPase.

Authors:  G R Lores Arnaiz; M A Gómez de Lima
Journal:  Acta Physiol Lat Am       Date:  1981

10.  Diuretic and natriuretic effect of a brain soluble fraction that inhibits neuronal Na+,K(+)-ATPase.

Authors:  S Nowicki; M A Enero; G Rodriguez de Lores Arnaiz
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

View more
  11 in total

1.  Kinetics of Na+, K+-ATPase inhibition by an endogenous modulator (II-A).

Authors:  A Reinés; C Peña; G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2000-01       Impact factor: 3.996

Review 2.  How many endobains are there?

Authors:  G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

3.  A comparative study between a brain Na+,K(+)-ATPase inhibitor (endobain E) and ascorbic acid.

Authors:  G Rodríguez de Lores Arnaiz; T Herbin; C Peña
Journal:  Neurochem Res       Date:  2003-06       Impact factor: 3.996

4.  Brain soluble fractions which modulate Na+, K+-ATPase activity likewise modify muscarinic receptor.

Authors:  G Rodríguez de Lores Arnaiz; P Schneider; C Peña
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

5.  Kinetics of Na+, K+-ATPase inhibition by a rat brain endogenous factor (II-E).

Authors:  T Herbin; C Peña; G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

6.  Kinetics of K(+)-p-nitrophenyl phosphatase stimulation by a brain soluble fraction.

Authors:  G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

7.  Differential properties between an endogenous brain Na+, K(+)-ATPase inhibitor and ouabain.

Authors:  C Peña; G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  1997-04       Impact factor: 3.996

8.  Modulation of aspartate release by ascorbic acid and endobain E, an endogenous Na+, K+ -ATPase inhibitor.

Authors:  M G Bersier; V Miksztowicz; C Peña; G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

9.  The effect of an endogenous Na+, K+-ATPase inhibitor on rat lens transparency and ultrastructure.

Authors:  Amanda Pellegrino de Iraldi; Clara Peña; Georgina Rodríguez de Lores Arnaiz
Journal:  Cell Mol Neurobiol       Date:  2003-04       Impact factor: 5.046

10.  High-affinity neurotensin receptor is involved in phosphoinositide turnover increase by inhibition of sodium pump in neonatal rat brain.

Authors:  Susana Pereyra-Alfonso; María Del Valle Armanino; Carolina Vázquez; Clara Peña; Georgina Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2008-08-29       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.